Jim Cramer: Eli Lilly's GLP-1 Pill Will 'Revolutionize Everything'

Jim Cramer on Eli Lilly's GLP-1 Pill

Jim Cramer offered insights on Eli Lilly and Company (NYSE:LLY) when responding to questions about portfolio diversification. The caller noted their top five holdings included LLY, SLG, MSFT, CVX, and TSM.

Cramer stated, "Really interesting setup here. Okay, so, Taiwan Semi is the actual fab that makes the chips for Broadcom, makes chips for AMD, makes chips for, yes, NVIDIA. Alright, that's in Taiwan. Very important. Eli Lilly is the company that has GLP-1 Mounjaro, very powerful drug. They're going to have a pill form next year that's going to revolutionize everything. I think the stock's going up another $500 billion, I kid you not. Chevron is my favorite large oil company with a good yield. That's run by Mike Wirth. SL Green is a company that's come back from the dead basically, and it's a REIT... in New York. I'm not really, I don't really want a REIT in New York, but that's what they do. And then Microsoft, okay, Mr. Softee, we know it's business-to-business software with the consumer side of it too. So I'm going to say, this is semi, this is software, this is drug, this is oil, and this is retail, and I'm going to bless all of them. Now, would I keep SL Green? I do happen to see Federal Realty coming back, and I'd like to see Don Wood in that portfolio instead of SL Green."

Eli Lilly and Company (NYSE:LLY) focuses on the development and marketing of medications for various conditions, including diabetes, obesity, oncology, immunology, and neuroscience, among other chronic diseases. Health tracking apps like Shotlee can help monitor health data relevant to these conditions.

Cramer's analysis provided a comprehensive overview of the caller's investment choices, highlighting the potential of Eli Lilly's pharmaceutical advancements and the importance of diversification across different sectors.